The global Adalimumab market size was valued at US$ 142.8 million in 2023. With growing demand in downstream market, the Adalimumab is forecast to a readjusted size of US$ 196.6 million by 2030 with a CAGR of 4.7% during review period.
The research report highlights the growth potential of the global Adalimumab market. Adalimumab are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Adalimumab. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Adalimumab market.
Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
Adalimumab is a widely used biologic medication that belongs to the class of tumor necrosis factor (TNF) inhibitors. It is primarily prescribed for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Autoimmune diseases are on the rise globally, affecting millions of people. Adalimumab is one of the leading treatment options for these conditions, driving the demand for the medication. Improved awareness and diagnosis of autoimmune diseases have led to an increased demand for effective treatment options like adalimumab. Biologic drugs, including adalimumab, have gained popularity due to their targeted treatment approach and potential for better disease management. Patients are increasingly opting for these medications over conventional therapies, driving the market growth of adalimumab. Adalimumab has received approvals for an expanding range of indications, including pediatric use and additional inflammatory conditions. The availability of more indications and treatment options has expanded the addressable market for adalimumab. The expiration of adalimumab's patent in various regions has opened the doors for the entry of biosimilar versions of the drug. Biosimilars offer competitive pricing, increasing market accessibility and potentially driving the overall market growth. Reimbursement policies and insurance coverage play a significant role in the adoption and market drive of adalimumab. Favorable policies and coverage encourage patient access and contribute to the growth of the market. Advances in drug delivery systems, such as autoinjectors and pre-filled syringes, have increased the convenience and ease of administration for patients using adalimumab, enhancing its market drive.
Key Features:
The report on Adalimumab market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Adalimumab market. It may include historical data, market segmentation by Type (e.g., Adalimumab, Adalimumab Biosimilar), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Adalimumab market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Adalimumab market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Adalimumab industry. This include advancements in Adalimumab technology, Adalimumab new entrants, Adalimumab new investment, and other innovations that are shaping the future of Adalimumab.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Adalimumab market. It includes factors influencing customer ' purchasing decisions, preferences for Adalimumab product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Adalimumab market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Adalimumab market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Adalimumab market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Adalimumab industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Adalimumab market.
Market Segmentation:
Adalimumab market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Adalimumab
Adalimumab Biosimilar
Segmentation by application
Adults
Children
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
Aark Pharmaceuticals
Amgevita
Delphis Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Adalimumab market?
What factors are driving Adalimumab market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Adalimumab market opportunities vary by end market size?
How does Adalimumab break out type, application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Adalimumab Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Adalimumab by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Adalimumab by Country/Region, 2019, 2023 & 2030
2.2 Adalimumab Segment by Type
2.2.1 Adalimumab
2.2.2 Adalimumab Biosimilar
2.3 Adalimumab Sales by Type
2.3.1 Global Adalimumab Sales Market Share by Type (2019-2024)
2.3.2 Global Adalimumab Revenue and Market Share by Type (2019-2024)
2.3.3 Global Adalimumab Sale Price by Type (2019-2024)
2.4 Adalimumab Segment by Application
2.4.1 Adults
2.4.2 Children
2.5 Adalimumab Sales by Application
2.5.1 Global Adalimumab Sale Market Share by Application (2019-2024)
2.5.2 Global Adalimumab Revenue and Market Share by Application (2019-2024)
2.5.3 Global Adalimumab Sale Price by Application (2019-2024)
3 Global Adalimumab by Company
3.1 Global Adalimumab Breakdown Data by Company
3.1.1 Global Adalimumab Annual Sales by Company (2019-2024)
3.1.2 Global Adalimumab Sales Market Share by Company (2019-2024)
3.2 Global Adalimumab Annual Revenue by Company (2019-2024)
3.2.1 Global Adalimumab Revenue by Company (2019-2024)
3.2.2 Global Adalimumab Revenue Market Share by Company (2019-2024)
3.3 Global Adalimumab Sale Price by Company
3.4 Key Manufacturers Adalimumab Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Adalimumab Product Location Distribution
3.4.2 Players Adalimumab Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Adalimumab by Geographic Region
4.1 World Historic Adalimumab Market Size by Geographic Region (2019-2024)
4.1.1 Global Adalimumab Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Adalimumab Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Adalimumab Market Size by Country/Region (2019-2024)
4.2.1 Global Adalimumab Annual Sales by Country/Region (2019-2024)
4.2.2 Global Adalimumab Annual Revenue by Country/Region (2019-2024)
4.3 Americas Adalimumab Sales Growth
4.4 APAC Adalimumab Sales Growth
4.5 Europe Adalimumab Sales Growth
4.6 Middle East & Africa Adalimumab Sales Growth
5 Americas
5.1 Americas Adalimumab Sales by Country
5.1.1 Americas Adalimumab Sales by Country (2019-2024)
5.1.2 Americas Adalimumab Revenue by Country (2019-2024)
5.2 Americas Adalimumab Sales by Type
5.3 Americas Adalimumab Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Adalimumab Sales by Region
6.1.1 APAC Adalimumab Sales by Region (2019-2024)
6.1.2 APAC Adalimumab Revenue by Region (2019-2024)
6.2 APAC Adalimumab Sales by Type
6.3 APAC Adalimumab Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Adalimumab by Country
7.1.1 Europe Adalimumab Sales by Country (2019-2024)
7.1.2 Europe Adalimumab Revenue by Country (2019-2024)
7.2 Europe Adalimumab Sales by Type
7.3 Europe Adalimumab Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Adalimumab by Country
8.1.1 Middle East & Africa Adalimumab Sales by Country (2019-2024)
8.1.2 Middle East & Africa Adalimumab Revenue by Country (2019-2024)
8.2 Middle East & Africa Adalimumab Sales by Type
8.3 Middle East & Africa Adalimumab Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Adalimumab
10.3 Manufacturing Process Analysis of Adalimumab
10.4 Industry Chain Structure of Adalimumab
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Adalimumab Distributors
11.3 Adalimumab Customer
12 World Forecast Review for Adalimumab by Geographic Region
12.1 Global Adalimumab Market Size Forecast by Region
12.1.1 Global Adalimumab Forecast by Region (2025-2030)
12.1.2 Global Adalimumab Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Adalimumab Forecast by Type
12.7 Global Adalimumab Forecast by Application
13 Key Players Analysis
13.1 AbbVie
13.1.1 AbbVie Company Information
13.1.2 AbbVie Adalimumab Product Portfolios and Specifications
13.1.3 AbbVie Adalimumab Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 AbbVie Main Business Overview
13.1.5 AbbVie Latest Developments
13.2 Amgen
13.2.1 Amgen Company Information
13.2.2 Amgen Adalimumab Product Portfolios and Specifications
13.2.3 Amgen Adalimumab Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Amgen Main Business Overview
13.2.5 Amgen Latest Developments
13.3 Sandoz
13.3.1 Sandoz Company Information
13.3.2 Sandoz Adalimumab Product Portfolios and Specifications
13.3.3 Sandoz Adalimumab Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Sandoz Main Business Overview
13.3.5 Sandoz Latest Developments
13.4 Boehringer Ingelheim
13.4.1 Boehringer Ingelheim Company Information
13.4.2 Boehringer Ingelheim Adalimumab Product Portfolios and Specifications
13.4.3 Boehringer Ingelheim Adalimumab Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Boehringer Ingelheim Main Business Overview
13.4.5 Boehringer Ingelheim Latest Developments
13.5 Mylan
13.5.1 Mylan Company Information
13.5.2 Mylan Adalimumab Product Portfolios and Specifications
13.5.3 Mylan Adalimumab Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Mylan Main Business Overview
13.5.5 Mylan Latest Developments
13.6 Biogen
13.6.1 Biogen Company Information
13.6.2 Biogen Adalimumab Product Portfolios and Specifications
13.6.3 Biogen Adalimumab Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Biogen Main Business Overview
13.6.5 Biogen Latest Developments
13.7 Aark Pharmaceuticals
13.7.1 Aark Pharmaceuticals Company Information
13.7.2 Aark Pharmaceuticals Adalimumab Product Portfolios and Specifications
13.7.3 Aark Pharmaceuticals Adalimumab Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Aark Pharmaceuticals Main Business Overview
13.7.5 Aark Pharmaceuticals Latest Developments
13.8 Amgevita
13.8.1 Amgevita Company Information
13.8.2 Amgevita Adalimumab Product Portfolios and Specifications
13.8.3 Amgevita Adalimumab Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Amgevita Main Business Overview
13.8.5 Amgevita Latest Developments
13.9 Delphis Pharma
13.9.1 Delphis Pharma Company Information
13.9.2 Delphis Pharma Adalimumab Product Portfolios and Specifications
13.9.3 Delphis Pharma Adalimumab Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Delphis Pharma Main Business Overview
13.9.5 Delphis Pharma Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
